Prostate Cancer

Prostate Cancer Drug Resistance Mediated by Epigenetic Changes

Prostate Cancer Drug Resistance Mediated by Epigenetic Changes

By

Epigenetic changes in the tumor microenvironment may explain why prostate cancer patients develop resistance to androgen signaling deprivation therapy.

Study Zeroes in on Cause of Castration-Resistant Prostate Cancer

Study Zeroes in on Cause of Castration-Resistant Prostate Cancer

By

Some prostate cancer cells lack androgen receptors, and they proliferate faster than those that express androgen receptors under androgen-deficient conditions.

Genetic Counseling Recommended for Advanced Prostate Cancer

Genetic Counseling Recommended for Advanced Prostate Cancer

By

A new white paper emphasizes the benefits of germline testing.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Heavy Alcohol Intake in Early Life May Significantly Increase Odds of High-Grade Prostate Cancer

Heavy Alcohol Intake in Early Life May Significantly Increase Odds of High-Grade Prostate Cancer

By

Recent analyses suggest that lifetime intake and early-life alcohol use may significantly contribute to the development of high-grade prostate cancer.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

IL-23 Drives Castration-Resistant Prostate Cancer

IL-23 Drives Castration-Resistant Prostate Cancer

By

A growing body of evidence points to infiltrating myeloid-derived suppressor cells as key players in tumor progression and acquired treatment resistance.

SBRT Appears Effective for Oligometastatic Prostate Cancer

SBRT Appears Effective for Oligometastatic Prostate Cancer

By

Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

First-Line Enzalutamide May Confer a Survival Benefit for Metastatic Castration-Resistant Prostate Cancer

First-Line Enzalutamide May Confer a Survival Benefit for Metastatic Castration-Resistant Prostate Cancer

By

Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Active Surveillance May Be a Good Option for Younger Men with Prostate Cancer

Active Surveillance May Be a Good Option for Younger Men with Prostate Cancer

By

The effect of age on outcomes in active surveillance is not well reported and requires further study.

Beverages Sweetened With Added Sugars May Increase the Risk of Prostate Cancer

Beverages Sweetened With Added Sugars May Increase the Risk of Prostate Cancer

By

Some prior evidence has linked increased sugar consumption to cancer development, but its impact on prostate cancer is unknown.

Gene Variant May Affect Response to Abiraterone in Certain Men with Prostate Cancer

Gene Variant May Affect Response to Abiraterone in Certain Men with Prostate Cancer

By

The breakdown of the medication abiraterone, which can be accelerated by the presence of a specific gene variant, produces drug metabolites that are suspected to play a role in the progression of prostate cancer to castration-resistant forms of disease.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

By

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

By

This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk Prostate Cancer

Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk Prostate Cancer

By

The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear.

High-Intensity Focused Ultrasound Therapy May Improve Survival in Nonmetastatic Prostate Cancer

High-Intensity Focused Ultrasound Therapy May Improve Survival in Nonmetastatic Prostate Cancer

By

Focal therapy targets may potentially reduce adverse events and provide better cancer control, but previous studies have been limited in scope.

New Therapeutic Directions in the Management of Prostate Cancer

New Therapeutic Directions in the Management of Prostate Cancer

By

According to experts, PARP inhibition, radiopharmaceuticals, and immunotherapy could revolutionize how prostate cancer is treated in the coming decade.

Enzalutamide Postpones Metastasis for a Subset of High-Risk Patients With Prostate Cancer

Enzalutamide Postpones Metastasis for a Subset of High-Risk Patients With Prostate Cancer

By

Treatment with enzalutamide decreased the risk of metastasis or death by 71% in patients diagnosed with nonmetastatic castration-resistant prostate cancer.

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Post-Radiotherapy Docetaxel for Intermediate-, High-Risk Prostate Cancer Is Not Beneficial

Post-Radiotherapy Docetaxel for Intermediate-, High-Risk Prostate Cancer Is Not Beneficial

By

A phase 3 trial involving men treated with radiotherapy for intermediate- or high-risk prostate cancer revealed no significant difference in biochemical disease-free survival.

PET/CT Accurately Localizes Recurrent Prostate Cancer

PET/CT Accurately Localizes Recurrent Prostate Cancer

By

Salvage therapy guided by 68Ga-PSMA11 PET/CT resulted in high biochemical response rates.

Abiraterone for mCRPC May Benefit Patients Who Are Black More Than Patients Who Are White

Abiraterone for mCRPC May Benefit Patients Who Are Black More Than Patients Who Are White

By

Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.

Prostate Cancer Vaccine Found Not To Improve Survival

Prostate Cancer Vaccine Found Not To Improve Survival

By

In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.

Abiraterone Plus Leuprolide Offers Edge in M0 Hormone-Naive Prostate Cancer

Abiraterone Plus Leuprolide Offers Edge in M0 Hormone-Naive Prostate Cancer

By

Abiraterone plus leuprolide compared with leuprolide decreased the risk of biochemical recurrence by 38%.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs